Drugs / TQB3558
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04408079 | Jun 2020 → Jul 2022 | cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3558 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04408079 ↗ |
| Action | Inhibit | “TQB3558 is a kinase inhibitor of the TRK protein family.” NCT04408079 ↗ |
| Route | Oral | “TQB3558 tablets administered orally once.” NCT04408079 ↗ |